检索结果-南通市图书馆

Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/miscrosatellite-stable type endometrial cancer:A case report

引用

World Journal of Clinical Cases 2022年第21期10卷 7474-7482页

作者： Chong-Ya Zhai Lu-Xi Yin Wei-Dong Han Department of Medical Oncology Xiasha CampusSir Run Run Shaw HospitalCollege of MedicineZhejiang UniversityHangzhou 310020Zhejiang ProvinceChina Department of Medical Oncology Sir Run Run Shaw HospitalCollege of MedicineZhejiang UniversityHangzhou 310020Zhejiang ProvinceChina

BACKGROUND endometrial cancer(EC)is one of the most common cancers of the female reproductive tract,and the incidence is increasing *** using programmed cell death-1(PD-1)inhibitors is an emerging research topic and treatment strategy for refractory gynecological ***,clinical management of EC with checkpoint inhibitors requires ***,we discuss a case of refractory proficient mismatch repair(pMMR)/miscrosatellitestable(MSS)EC treated with a combination of PD-1 and angiogenesis inhibitors and offer a review of the pathophysiology and clinical outcomes based on previous *** SUMMARY A 62-year-old woman diagnosed with invasive or metastatic EC in 2015 was treated with six courses of chemotherapy and refused further *** years later,she developed chest pain,and lung biopsy indicated thyroid transcription factor-1(-),Napsin A(-),estrogen receptor(+),progesterone receptor(+),anaplastic lymphoma kinase(D5F3)(-),and receptor tyrosine kinase(D4D6)(-)metastatic *** testing results showed low tumor mutation burden,pMMR,PD ligand 1(-),MSS,and HLA-class 1 heterogeneous *** patient was started on toripalimab combined with nab-paclitaxel for seven cycles(every 3 wk),but this regimen was terminated because of an intolerable chemotherapy adverse *** disease progressed in 2020,and the patient’s treatment was switched from nab-paclitaxel to anlotinib,while immunotherapy using toripalimab was *** patient achieved a major partial response with well-tolerated toxicities,and treatment is *** Molecular testing is advised for clinical classifications of EC owing to its high *** this case,the patient had pMMR/MSS EC and achieved a positive outcome with combination PD-1 inhibitor *** results warrant further clinical exploration.

关键词： refractory endometrial cancer Proficient mismatch repair Miscrosatellite-stable Immunotherapy Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：